VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ETON
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ETONEton Pharmaceuticals, Inc.
$63.88$1.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksETONFinancials

Eton Pharmaceuticals, Inc. (ETON) Income Statement

9Y historyFree accessUpdated daily

Revenue scaled from $9.1M to $57.9M and gross margin expanded from 35.0% to 76.5% over recent quarters, but trailing net margin remains negative at -5.8%, suggesting profitability is not yet consistent.

Income StatementBalance SheetCash FlowRatios

ETON Income Statement

Annual statement

ETON Income Statement

Eton Pharmaceuticals, Inc. (ETON) annual income statement — 9-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Sales/Revenue141.06M79.95M39.01M31.64M21.25M21.83M39K959K00
Revenue Growth %100.61%104.94%23.29%48.9%-2.66%55879.49%-95.93%---
Cost of Goods Sold43.51M37.21M15.6M10.58M6.93M2.62M286K453K63K13K
COGS % of Revenue-46.54%39.99%33.44%32.62%12.01%733.33%47.24%--
Gross Profit97.55M42.74M23.41M21.06M14.32M19.21M-247K506K-63K-13K
Gross Margin %69.15%53.46%60.01%66.56%67.38%87.99%-633.33%52.76%--
Gross Profit Growth %-82.56%11.16%47.09%-25.46%7876.92%-148.81%903.17%-384.62%-
Operating Expenses56.86M42.67M26.01M22.25M22.58M20.7M26.86M19.11M10.32M7.14M
OpEx % of Revenue-53.37%66.67%70.33%106.24%94.83%68882.05%1992.39%--
Selling, General & Admin46.95M35.82M22.75M18.93M18.58M14.47M12.76M7.55M4.69M3.21M
SG&A % of Revenue-44.8%58.32%59.83%87.44%66.27%32717.95%787.49%--
Research & Development9.92M7.76M3.25M3.32M4M6.24M14.1M11.55M5.63M3.93M
R&D % of Revenue-9.71%8.34%10.5%18.8%28.56%36164.1%1204.9%--
Other Operating Expenses0-916K00000000
Operating Income40.69M72K-2.6M-1.19M-8.26M-1.5M-27.11M-18.6M-10.32M-7.15M
Operating Margin %28.84%0.09%-6.66%-3.77%-38.87%-6.85%-69515.38%-1939.62%--
Operating Income Growth %-102.77%-117.87%85.57%-452.51%94.49%-45.75%-80.22%-44.35%-
EBITDA45.66M4.12M-1.45M-291K-6.49M-1.03M-26.46M-18.15M-10.26M-7.14M
EBITDA Margin %32.37%5.15%-3.72%-0.92%-30.52%-4.73%-67846.15%-1893.01%--
EBITDA Growth %6395.45%383.67%-398.63%95.51%-527.88%96.1%-45.75%-76.97%-43.73%-
D&A (Non-Cash Add-back)4.98M4.04M1.15M901K1.77M462K651K447K63K13K
EBIT39.47M223K-1.8M-689K-9.02M-1.96M-27.11M-18.6M-10.32M-7.16M
Net Interest Income-2.4M-4.78M-2M-1.06M-955K-1.04M-889K281K00
Interest Income0000000281K164K52.5K
Interest Expense2.4M4.78M2M1.06M955K1.04M889K000
Other Income/Expense-3.62M-4.63M-1.21M503K-761K-460K-859K281K-2.42M-6K
Pretax Income37.06M-4.56M-3.81M-689K-9.02M-1.96M-27.97M-18.32M-12.74M-7.16M
Pretax Margin %26.27%-5.7%-9.76%-2.18%-42.45%-8.95%-71717.95%-1910.32%--
Income Tax-12.8M43K15K247K000000
Effective Tax Rate %-34.54%-0.94%-0.39%-35.85%0%0%0%0%0%0%
Net Income49.86M-4.6M-3.82M-936K-9.02M-1.96M-27.97M-18.32M-12.74M-7.16M
Net Margin %35.35%-5.75%-9.8%-2.96%-42.45%-8.95%-71717.95%-1910.32%--
Net Income Growth %846.24%-20.35%-308.44%89.62%-361.43%93.01%-52.67%-43.8%-78.03%-
Net Income (Continuing)49.86M-4.6M-3.82M-936K-9.02M-1.96M-27.97M-18.32M-12.74M-7.16M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)1.50-0.17-0.15-0.04-0.36-0.08-1.33-1.02-1.99-0.41
EPS Growth %711.96%-13.33%-310.96%89.86%-363.92%94.17%-30.39%48.74%-385.37%-
EPS (Basic)--0.17-0.15-0.04-0.36-0.08-1.33-1.02-1.99-0.41
Diluted Shares Outstanding33.26M26.91M25.89M25.65M25.15M25.21M21.01M17.76M6.42M17.46M
Basic Shares Outstanding28.66M26.91M25.89M25.64M25.15M25.21M21.01M17.76M6.42M17.46M
Dividend Payout Ratio----------

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Thin margins and dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Compounding Through Orphan Product Scale-Up

According to reported quarterly figures, ETON's revenue rose from $9.1M in 2024Q2 to $57.9M in 2026Q3, with the latest quarter up 157.9% year over year, indicating a sharp acceleration in demand for its specialty portfolio.

The progression from roughly $9M to nearly $58M per quarter suggests that orphan and pediatric formulations are gaining real commercial traction rather than reflecting a one-time launch stocking effect. The consistency of triple-digit growth across several quarters points to durable prescription demand, though the base was small and the sequential jump in 2026Q3 warrants scrutiny for wholesaler inventory timing. Investors should monitor whether growth holds once the initial launch cohort matures.

Gross Margin Rebuilt Above Sixty Percent

Based on reported figures, ETON's gross margin expanded from 35.0% in 2025Q3 to 76.5% in 2026Q3, a level that suggests a shift toward higher-value wholly controlled products and better unit economics.

The recovery from the mid-2025 trough implies that mix, rather than pricing alone, is driving improvement, as lower-margin hospital injectables appear to be a diminishing share of revenue. The 2026Q3 figure is notably high relative to the prior 53-63% range, so it may reflect favorable royalty timing or one-off items that should not be extrapolated without confirmation. Sustained margins above 60% would support the premium-niche thesis.

Operating Leverage Emerging but Unproven

As reported in financial statements, ETON's operating margin moved from -7.8% in 2025Q2 to 39.7% in 2026Q3, but trailing operating margin remains near 0.1%, showing that gains have been recent and uneven.

Operating income turning sharply positive in the latest quarter while SG&A rose only modestly relative to revenue indicates the fixed-cost base is being absorbed, which is the core of operating leverage. However, the near-zero trailing operating margin means the earlier quarters still dominate the cumulative picture. Whether SG&A continues to grow slower than revenue in upcoming periods will determine if this is structural or a transitory quarter.

Quarterly Profit Beat Versus Trailing Losses

Based on EDBL's reported figures, the latest quarter delivered diluted EPS of $1.06 against a trailing net margin of -5.8%, a gap that raises questions about how much of the recent earnings reflects recurring operations.

A single quarter with net income of $35.2M on $57.9M revenue exceeds what operating income alone would suggest, pointing to possible non-operating or tax-related contributions that are not detailed in the provided data. Stock-based compensation of $3.3M is modest relative to net income and does not appear to be distorting results materially. Earnings quality should be treated as provisional until several consecutive quarters confirm the run-rate.

Growth Quality and Margin Sustainability Risks

The strongest bear case is that ETON's 157.9% quarterly growth and 76.5% gross margin may reflect launch timing and one-time items, while trailing net margin of -5.8% and ROE of -18.2% show the business has not yet proven durable profitability.

Short-sellers would likely argue that the 2026Q3 spike coincides with inventory stocking and possible milestone recognition, both of which can inflate a single quarter without signaling sustainable demand. The leverage profile, with debt-to-equity of 1.19, combined with negative returns on equity, suggests the company still depends on external capital structure to fund growth. Investors should monitor whether the next two quarters show revenue holding near current levels and operating income remaining positive.

ETON — Frequently Asked Questions

Quick answers to the most common questions about buying ETON stock.

What was Eton Pharmaceuticals, Inc.'s (ETON) revenue in 2025?

For fiscal year 2025, Eton Pharmaceuticals, Inc. (ETON) reported total revenue of $80.0M.

Is Eton Pharmaceuticals, Inc. (ETON) profitable?

Eton Pharmaceuticals, Inc. (ETON) reported a net loss of $4.6M for the fiscal year ending 2025.

What is Eton Pharmaceuticals, Inc.'s operating profit margin?

Eton Pharmaceuticals, Inc. (ETON) reported an operating income of $0.1M, resulting in an operating profit margin of 0.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Eton Pharmaceuticals, Inc.'s gross profit and gross margin?

Eton Pharmaceuticals, Inc. (ETON) generated $42.7M in gross profit for the year, representing a gross profit margin of 53.5%. This demonstrates the company's core pricing power and production efficiency.